Low-dose glucagon to prevent low blood sugar during exercise in type 1 diabetes
Tests low-dose glucagon before exercise in adults with type 1 diabetes using automated insulin delivery.
Plain-language title generated from the registry record
Registry title: The Postprandial Hypo-Avoid Study
Key facts
- Where
- Herlev, DenmarkSee the site
- Phase
- Phase 4
Where in Denmark
- Steno Diabetes Center CopenhagenHerlev, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Steno Diabetes Center Copenhagen
- Trial code
- NCT07427251
- Record updated
- 13 August 2026
- Original description
The objective of the study is to evaluate whether pre-exercise administration of low-dose subcutaneous glucagon prevents or attenuates exercise-induced declines in plasma glucose concentration during and after moderate-intensity continuous exercise (MICE) performed approximately 90 minutes after a meal in adults with type 1 diabetes using an automated insulin delivery (AID) system.Read full original descriptionShow less
Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglycemia in People With Type 1 Diabetes
The objective of the study is to evaluate whether pre-exercise administration of low-dose subcutaneous glucagon prevents or attenuates exercise-induced declines in plasma glucose concentration during and after moderate-intensity continuous exercise (MICE) performed approximately 90 minutes after a meal in adults with type 1 diabetes using an automated insulin delivery (AID) system.
The primary endpoint is the difference in the change in plasma glucose (PG) from exercise initiation to the nadir during exercise and through the 2-hour post-exercise period between the glucagon (GCN) and carbohydrate (CHO) visits.
Inclusion: Age ≥ 18 years; Type 1 diabetes ≥ 2 years; Using an automated insulin delivery system for ≥ 3 months; NovoRapid or Fiasp use ≥1 week; Proficiency in carbohydrate counting.
Exclusion: Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (methods are considered adequate for study enrolment for females: an intrauterine device, hormonal contraception (birth control pills, implant, patch, vaginal ring or injection), a single partner who is sterile or infertile, or sexual abstinence. Contraception is required throughout the study duration. Sterilized or postmenopausal women (>12 months since last period) are not required to use contraception); Allergies to lactose or glucagon; Known or suspected allergies to glucagon or related products; History of hypersensitivity or allergic reaction to glucagon or lactose; Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation; Patients with diagnosed pheochromocytoma, insulinoma or gastroparesis; Lack of compliance with key study procedures at the discretion of the investigator; Inability to understand the individual information and to give informed consent.